Andrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $81.17, for a total value of $649,360.00. Following the sale, the chief financial officer now directly owns 96,720 shares in the company, valued at approximately $7,850,762.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, May 20th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The shares were sold at an average price of $74.99, for a total value of $599,920.00.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded up $2.37 during midday trading on Monday, reaching $84.00. The company had a trading volume of 666,882 shares, compared to its average volume of 792,216. The company has a fifty day simple moving average of $74.55 and a two-hundred day simple moving average of $69.94. The firm has a market cap of $9.14 billion, a price-to-earnings ratio of -19.58 and a beta of 0.97. Vaxcyte, Inc. has a 1-year low of $44.20 and a 1-year high of $85.61.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.28. Analysts expect that Vaxcyte, Inc. will post -3.96 EPS for the current year.

Institutional Trading of Vaxcyte

Hedge funds have recently modified their holdings of the business. Darwin Global Management Ltd. raised its position in Vaxcyte by 374.3% during the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after buying an additional 2,170,845 shares during the period. Vanguard Group Inc. lifted its position in shares of Vaxcyte by 15.2% in the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock worth $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. Norges Bank purchased a new stake in shares of Vaxcyte in the fourth quarter worth approximately $57,494,000. Capital Research Global Investors boosted its holdings in shares of Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after purchasing an additional 700,414 shares during the period. Finally, Janus Henderson Group PLC grew its position in Vaxcyte by 9.9% during the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock valued at $524,117,000 after purchasing an additional 692,492 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on PCVX. Needham & Company LLC reiterated a “buy” rating and issued a $95.00 price target on shares of Vaxcyte in a research report on Friday, June 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Thursday, June 20th.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.